Physiomics Regulatory News (PYC)

2 March 2022

Physiomics plc

("Physiomics" or "the Company")

Notice of Interim Results and Investor Presentation

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, will issue its interim results for the six months ended 31 December 2021 on Monday 7 March 2022.

The Company is further pleased to announce that Dr Jim Millen will provide a live presentation relating to its interim results via the Investor Meet Company platform on Tuesday 8 March 2022 at 2:00pm GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and "add to meet" PHYSIOMICS PLC via the following link: https://www.investormeetcompany.com/physiomics-plc/register-investor. Investors who already follow PHYSIOMICS PLC on the Investor Meet Company platform will automatically be invited.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended.

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

For more information please visit:

www.physiomics.co.uk 

www.twitter.com/Physiomics 

www.linkedin.com/company/physiomics-plc/